Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development : A Focus on Early Phase Clinical Studies / / edited by Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch |
Edizione | [1st ed. 2015.] |
Pubbl/distr/stampa | London : , : Springer London : , : Imprint : Springer, , 2015 |
Descrizione fisica | 1 online resource (316 p.) |
Disciplina |
610
615 615.19 616 616.39 616.46 616462 |
Soggetto topico |
Medicine
Internal medicine Diabetes Metabolic diseases Pharmacology Pharmaceutical technology Medicine/Public Health, general Internal Medicine Metabolic Diseases Pharmacology/Toxicology Pharmaceutical Sciences/Technology |
ISBN | 1-4471-4920-3 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | 1. Review of physiology/pathophysiology -- 2. Methods for assessing insulin action in humans -- 3. Assessment of insulin secretion -- 4. Measurement of ectopic fat in liver and muscle using magnetic resonance spectroscopy -- 5. Isotopic tracers for the measurement of metabolic flux -- 6. Measuring food intake in clinical drug development -- 7. Measurement of energy expenditure -- 8. Assessment of body composition -- 9. Assessment of cardiovascular safety of new diabetes drugs. |
Record Nr. | UNINA-9910300201603321 |
London : , : Springer London : , : Imprint : Springer, , 2015 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease : A Focus on Early Phase Clinical Drug Development / / edited by Andrew J. Krentz, Christian Weyer, Marcus Hompesch |
Edizione | [2nd ed. 2019.] |
Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
Descrizione fisica | 1 online resource (557 pages) |
Disciplina | 616.4620072 |
Soggetto topico |
Diabetes
Metabolic diseases Pharmacology Metabolic Diseases Pharmacology/Toxicology |
ISBN | 3-030-11748-0 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Part 1: Review of Clinical Investigative Methods -- Chapter 1: Quantifying Insulin Action in Humans -- Chapter 2: Assessment of Islet Alpha- and Beta-Cell Function -- Chapter 3: Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins -- Chapter 4: Measurement of Energy Expenditure -- Chapter 5: QUANTIFYING APPETITE AND SATIETY -- Chapter 6: Non-invasive quantitative magnetic resonance imaging and spectroscopic biomarkers in nonalcoholic fatty liver disease and other cardiometabolic diseases associated with ectopic fat deposition -- Chapter 7: Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development -- Chapter 8: Positron emission tomography and computed tomography measurement of brown fat thermal activation: key tool for developing novel pharmacotherapeutics for obesity and diabetes -- Chapter 9: Isotopic Tracers for the Measurement of Metabolic Flux Rates -- Chapter 10: Role of Tissue Biopsy in Drug Development for NonAlcoholic Fatty Liver Disease and Other Metabolic Disorders -- Chapter 11: Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH -- Chapter 12: Omics: Potential role in early phase drug development -- Part 2: Preclinical Drug Development and Transitioning to Clinical Studies -- Chapter 13: Peptide Drug Design for Diabetes & Related Metabolic Diseases -- Chapter 14: ANIMAL MODELS OF TYPE 2 DIABETES, OBESITY AND NONALCOHOLIC STEATOHEPATITIS – CLINICAL TRANSLATABILITY AND APPLICABILITY IN PRECLINICAL DRUG DEVELOPMENT -- Chapter 15: Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c -- Chapter 16: Emerging Circulating Biomarkers For The Diagnosis And Assessment Of Treatment Responses In Patients With Hepatic Fat Accumulation, Nash And Liver Fibrosis -- Chapter 17: Quantitative Approaches in Translational Cardiometabolic Research: An Overview -- Chapter 18: Transitioning from Preclinical to Clinical Drug Development -- Chapter 19: Regulatory Considerations for Early Study and Clinical Development of Drugs for Diabetes, Obesity, NonAlcoholic Steatohepatitis (NASH) and other Cardiometabolic Disorders -- Chapter 20: Early Phase Metabolic Research with Reference to Special Populations. |
Record Nr. | UNINA-9910337481203321 |
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|